论文部分内容阅读
目的:观察血必净注射液减轻重症创伤患者全身性炎症反应的临床疗效,探讨其能否调节患者机体内细胞因子,为临床进一步应用提供参考依据。方法:选取132例重症创伤患者,按随机数表法平均分为对照组及治疗组各66例。对照组采用常规治疗措施,并根据患者具体情况给予特殊治疗。治疗组则在对照组治疗用药基础上,静脉滴注血必净注射液。两组患者治疗前后均利用双抗夹心酶联免疫吸附法对血液中肿瘤坏死因子-α(TNF-α)、IL-6、IL-8等指标进行检测,并进行APACHEⅡ评分。比较患者上述各项观察指标的差别及患者病死率、EICU住院时间以及院内感染率。结果:治疗前后,两组患者血液中TNF-α、IL-6、IL-8水平均有所下降,APACHEⅡ评分同比下降,且治疗组上述指标下降幅度均大于对照组,差异有统计学意义(P<0.05)。治疗组院内感染率、死亡率及EICU住院时间均小于对照组,除两者EICU住院时间差异无统计学意义外,余下指标差异均有统计学意义(P<0.05)。结论:重症创伤患者早期应用血必净注射液能有效地抑制炎症反应,降低院内感染率,提高生存率。
Objective: To observe the clinical efficacy of Xuebijing injection in reducing the systemic inflammatory response in patients with severe trauma, and to explore whether it can regulate the cytokines in the body of patients with severe traumatic injury so as to provide a reference for clinical further application. Methods: 132 patients with severe traumatic injury were selected and randomly divided into control group and treatment group according to random number table method. Control group using conventional treatment, and according to the specific circumstances of patients given special treatment. Treatment group in the control group based on the medication, intravenous Xuebijing injection. Tumor necrosis factor-α (TNF-α), IL-6, IL-8 and other indicators of blood were detected by double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) before and after treatment in both groups. The differences between the above indicators and patient mortality, EICU hospital stay and nosocomial infection rates were compared. Results: Before and after treatment, the blood levels of TNF-α, IL-6 and IL-8 in both groups decreased and the APACHEⅡ score decreased compared with the same period of last year. The decrease rate of the above indexes in the treatment group was greater than that in the control group (the difference was statistically significant P <0.05). The hospital infection rate, mortality and EICU hospitalization time in the treatment group were less than those in the control group. There was no significant difference in hospitalization time between the two groups (P <0.05). Conclusion: The application of Xuebijing Injection in the early stage of severe traumatic injury can effectively inhibit the inflammatory reaction, reduce the nosocomial infection rate and improve the survival rate.